An interventional study of Meditation + Usual Care in Glaucoma, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Not yet recruiting. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Not applicable, Interventional, and Other
Glaucoma is a chronic disease that causes loss of vision and potentially blindness as a result of optic nerve damage, often due to increased intraocular pressure. Glaucoma is currently the leading cause of irreversible blindness worldwide.1 In 2020, 4.1 million and 3.6 million adults over the age of 50 suffered from mild to severe glaucoma-induced visual impairment and blindness, respectively.1 However, these figures are likely underestimated since glaucoma can remain asymptomatic until later stages in disease progression.2 The relaxation response evoked by mind-body interventions, such as breathing exercises and meditation, is known to reduce stress and improve quality of life (QOL). In a recent study, mindfulness-based meditation was found to reduce intraocular pressure and improve QOL in patients with glaucoma.3 A feasibility study will be conducted using a mixed-method design to assess the feasibility of the online delivery of meditation for potentially enhancing the QOL and reducing stress in glaucoma patients. Upon recruitment, participants will undergo blocked randomization to either the intervention arm or usual care arm. Participants in each arm will complete online questionnaires at baseline and weeks 1, 3, 6, and 12 to collect data on health-related quality of life (HRQOL), perceived stress, and behaviour using REDCap. REDCap is an online data collection and survey tool hosted by the Office of Research Services of Lawson Research Institute. Our study can help to assess the feasibility of conducting a study on breathing exercises followed by meditation to assess its effects in a sample of patients with glaucoma.
1,419 studies on the registry are indexed under Glaucoma; 223 are open to participants now.
This study's planned enrollment of 158 is above the median of 61 across 964 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's is the lead sponsor of 331 studies on the registry; 137 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Meditation + Usual Care
Meditation is a guided technique that helps to reduce stress, therefore inducing physiological and mental relaxation whilst the eyes are shut.
Incidence of Quality of Life as measured by GQOL- 15 in Glaucoma Patients
HRQoL will be assessed using Glaucoma Quality of Life-15 (GQL-15). GQL-15 is a disease-specific, validated, self-administered questionnaire designed to measure HRQoL in patients with glaucoma. The questionnaire comprises of 15 items on daily functioning across 5 factors: central and near vision (2 items), peripheral vision (6 items), glare and dark adaptation (6 items), and outdoor mobility (1 item). Patients rate these questions on a 5-point Likert scale of difficulty ranging from "1 = no difficulty" to "5 = severe difficulty".
Time frame: Data will be collected at baseline and post-intervention at Week 1, 3, 6, and 12.
Incidence of Stress as Measured by PSS-10 in Glaucoma Patients
The Perceived Stress Scale (PSS-10) is a 10-item questionnaire widely used to measure the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. The scale also includes several direct queries about current levels of experienced stress. Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress. Scores ranging from 0-13 would be considered low stress; scores ranging from 14-26 would be considered moderate stress; and scores ranging from 27-40 would be considered high perceived stress.
Time frame: Data will be collected at baseline and post-intervention at Week 1, 3, 6, and 12.
Incidence of Behavior as measured by Consideration of Future Consequences - 14 (CFC-14) in Glaucoma Patients
In previous research, consideration of future consequences (CFC) has been recognized as a critical factor influencing individuals' engagement in health-promoting behaviors. Strathman et al. initially developed a 12-item unidimensional Consideration of Future Consequences (CFC) scale to measure individual differences in temporal orientation. This scale assesses the degree to which individuals consider the potential impact of their current behavior on immediate or distant outcomes.38 Low CFC scores indicate that individuals are more inclined to pursue immediate rewards, whereas high scores are observed among individuals who prioritize future advantages and sacrifice immediate gratification.
Time frame: Data will be collected at baseline and post-intervention at Week 1, 3, 6, and 12.
No study locations are listed for this record.
Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.
Of 229 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 24 months is below that.
Counting every sponsor, half of 287 studies reached it within 30 months; a quarter within 12 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's →